Drug Profile

HRS 9531

Alternative Names: HRS-9531; KAI-9531

Latest Information Update: 10 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Fujian Shengdi Pharmaceutical
Class Antihyperglycaemics; Obesity therapies; Peptides
Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Obesity; Type 2 diabetes mellitus

Most Recent Events

02 Sep 2025 Fujian Shengdi Pharmaceutical plans a phase I trial for Obesity in China (PO, Tablet) (NCT07150962)
25 Jul 2025 Phase-III clinical trials in Type 2 diabetes mellitus in China (unspecified route) (NCT07060456)
15 Jul 2025 Kailera Therapeutics announces intention to submit NDA for Obesity in China

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com